Johnson & Johnson’s Janssen Pharmaceutical announced that the European Commission has granted marketing authorization for Akeega in the form of a dual action tablet, given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA1/2 mutations in whom chemotherapy is not clinically indicated.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ: